Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences (Nasdaq: SLDB) announced it will participate in two upcoming investor conferences focused on healthcare.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Solid Biosciences (Nasdaq: SLDB) announced it will participate in two upcoming investor conferences focused on healthcare.
President and CEO Bo Cumbo will present at the Jefferies Global Healthcare Conference on June 3, 2026, and at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026.
Details
News Market Reaction – SLDB
On Jun 1, the day this news came out, SLDB closed 2.04% below the previous close.
Data tracked by StockTitan Argus for the Jun 1 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:
- Jefferies Global Healthcare Conference
Bo Cumbo, President and CEO, will be presenting on Wednesday, June 3, 2026, at 7:35 a.m. ET.
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for 90 days on the Events page.
- Goldman Sachs 47th Annual Global Healthcare Conference
Mr. Cumbo will be presenting on Monday, June 8, 2026, at 4:00 p.m. ET.
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for 90 days on the Events page.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Senior Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.